Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants?
Tóm tắt
Coronavirus disease 2019 (COVID-19) has been associated with an increased risk of thromboembolic complications due to systemic coagulation activation. Little is known about the role of direct anticoagulants (DOACs) in COVID-19 related thrombosis. In this audit we sought to distinguish COVID-19 hospitalised patients with a diagnosis of venous thromboembolism (VTE) and record their outcomes over a period of 3 months (01/02/2020–30/04/2020). A total of 1583 patients were diagnosed with laboratory proven COVID-19 disease. Amongst them, 38 patients (0.82%) suffered VTE (median age 68 years, male/female: 20/18). VTE was the presenting symptom on admission in 71%. Pulmonary embolism was diagnosed in 92% of patients; 5 patients required intensive care and 3 underwent thrombolysis. 27 patients received initial treatment with unfractionated heparin/low molecular weight heparin (LMWH) while 10 were treated with direct anticoagulants (DOACs). After a median follow up of 25 days, 29 (76%) patients were alive while 5 were still hospitalised. Most patients (83%) were discharged on DOACs, no VTE recurrence or bleeding was recorded post-discharge. Our results suggest that direct anticoagulants could be a safe and effective treatment option in selected COVID-19 positive patients who have suffered venous thromboembolism.
Tài liệu tham khảo
B Bikdeli MV Madhavan D Jimenez T Chuich I Dreyfus Driggin Ev 2020 COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up J Am Coll Cardiol https://doi.org/10.1016/j.jacc.2020.04.031
J Helms C Tacquard F Severac I Leonard-Lorant M Ohana X Delabranche 2020 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Intensive Care Med https://doi.org/10.1007/s00134-020-06062-x
JF Llitjos M Leclerc C Chochois JM Monsallier M Ramakers M Auvray 2020 High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients J Thromb Haemost https://doi.org/10.1111/jth.14869
C Lodigiani G Iapichino L Carenzo M Cecconi P Ferrazzi T Sebastian 2020 Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy Thromb Res 191 9 14 https://doi.org/10.1016/j.thromres.2020.04.024
S Middeldorp M Coppens TF Haaps van M Foppen AP Vlaar MCA Müller 2020 Incidence of venous thromboembolism in hospitalized patients with COVID-19 J Thromb Haemost https://doi.org/10.1111/jth.14888
C Hermans C Lambert 2020 Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis J Thromb Haemost https://doi.org/10.1111/jth.14845
S Schulman C Kearon Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis 2005 Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 692 694
S Cui S Chen X Li S Liu F Wang 2020 Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia J Thromb Haemost https://doi.org/10.1111/jth.14830
HJ Schunemann M Cushman AE Burnett SR Kahn J Beyer-Westendorf FA Spencer 2018 American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and non-hospitalized medical patients Blood Adv 2 22 3198 3225
W Lester K Gomez S Shapiro K Dabhi M Laffan 2019 NICE NG89 recommendations for extended pharmacological thromboprophylaxis—is it justified and is it cost effective: a rebuttal from the British Society for Haematology Br J Haematol 186 5 790 791 https://doi.org/10.1111/bjh.16007
N Tang H Bai X Chen J Gong D Li Z Sun 2020 Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy J Thromb Haemost 18 5 1094 1099 https://doi.org/10.1111/jth.14817
Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost 18(5):1020–1022. https://doi.org/10.1111/jth.14821
CT Esmon 2014 Targeting factor Xa and thrombin: impact on coagulation and beyond Thromb Haemost 111 4 625 633 https://doi.org/10.1160/TH13-09-0730
GD Barnes A Burnett A Allen M Blumenstein NP Clark A Adam Cuker 2020 Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum J Thromb Thrombol 50 1 72 81 https://doi.org/10.1007/s11239-020-02138-z
S Testa P Prandoni O Paoletti R Morandini M Tala C Dellanoce 2020 Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience J Thromb Haemost https://doi.org/10.1111/jth.14871
Kartsios C, Kaparou M, Payne R, Philpotts L, Beale K, Fowler M et al (2017). Measurement of apixaban and rivaroxaban levels in real life clinical practice; an instrument to improve anticoagulation management? Abstracts of the XXVI Congress of the International Society on Thrombosis and Haemostasis, July 8–13, 2017.